CYP2D6 and breast carcinoma: Therefore, the current study supports the TDM for breast cancer patients under tamoxifen treatment, since the effectiveness of the therapy is related to the levels of endoxifen, which is dependent on several unknown factors that go beyond CYP2D6 phenotype.30, 31